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Systemic Protein Therapy for Recessive
Dystrophic Epidermolysis Bullosa: How
Far Are We from Clinical Translation?
Alain Hovnanian1,2,3
In this issue, Woodley et al. report restoration of anchoring fibril formation and
dermal–epidermal adherence in a murine model of recessive dystrophic epider-
molysis bullosa (RDEB) by intravenous injection of recombinant human type VII
collagen. This work follows a previous report by the same group of the surprising
capability of intradermally injected type VII collagen protein to reverse RDEB, and
it opens new therapeutic avenues.
Journal of Investigative Dermatology (2013) 133, 1719–1721. doi:10.1038/jid.2013.137
Dystrophic epidermolysis bullosa (DEB)
is a group of heritable mechano-bullous
skin diseases characterized by skin fra-
gility, separation of the epidermis from
the dermis, milia formation, and scar-
ring (Fine et al., 2008). DEB is
transmitted in either a recessive (RDEB)
or a dominant (DDEB) manner. All
forms of DEB are caused by mutations
in COL7A1-encoding type VII collagen
that forms anchoring fibrils (AFs) at the
basement membrane zone (BMZ).
Patients with DEB show absent or
reduced and abnormal AF. The most
severe RDEB forms present with
extensive skin erosions, fusion of
fingers and toes, joint contractures, and
esophageal strictures, which cause
severe dysphagia and malnutrition.
Skin infections, anemia, and aggressive
squamous cell carcinomas are frequent
complications. DEB remains to be a
group of diseases that have no satis-
factory treatments.
Gene and cell therapy approaches
Initial gene therapy studies used in vivo
intradermal injection of gene-corrected
DEB fibroblasts or lentiviral vectors
expressing C7. After the first successful
transplantation of gene-corrected ker-
atinocyte autografts in a patient with
junctional EB (Mavilio et al., 2006),
several laboratories have developed
ex vivo transplantation of epithelia or
skin equivalents genetically corrected
with classical or self-inactivating
retroviral COL7A1 vectors (Siprashvili
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et al., 2010; Titeux et al., 2010), and
two clinical trials have been initiated.
In parallel, intradermal injection of
allogenic fibroblasts has shown
the effectiveness of cell therapy
(Wong et al., 2008). However, these
approaches require multiple injections
and/or grafting. To address the
extensive nature of the skin and
mucosal lesions in RDEB, alternative
strategies using systemic delivery
of therapeutic agents have been
developed. Injection of genetically
engineered human fibroblasts
overexpressing C7 into the systemic
circulation of a murine model was
reported to deliver C7 at wound sites
where they were incorporated into the
skin’s BMZ, forming AF (Woodley
et al., 2007). Recently, bone marrow
and cord blood transplantation of
HLA-matched donors led to clinical
improvement in patients with severe
disease (Wagner et al., 2010).
Protein replacement: from local to
systemic delivery
In the case of RDEB, protein replace-
ment consists in delivering recombinant
human type VII collagen (C7) protein
locally or systemically. This approach
demonstrated unexpected efficacy when
intradermally injected human C7 was
reported to incorporate stably into the
BMZ of wild-type mice, as well as into
regenerated human RDEB equivalent
skin transplanted onto immune-compro-
mised mice (Woodley et al., 2004).
Injection of C7 corrected the
subepidermal blistering and restored
type VII collagen expression in the
BMZ for at least 2 months after a
single injection. Immunogold labeling
showed that the injected C7 was
organized into AF structures. These
results were supported further by
intradermal injection of human C7 in a
murine model of RDEB (Remington
et al., 2009). The injected human C7
incorporated stably into the BMZ of
RDEB mice, formed AF, and corrected
the disease phenotype, leading to
markedly prolonged survival. Remar-
kably, the treated RDEB mice deve-
loped circulating anti-human C7 anti-
bodies that did not bind to the mouse’s
BMZ, nor did it prevent AF formation.
Finally, treatment of the mice with an
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anti-CD40L mAb prevented the produc-
tion of anti-human C7 antibodies.
The question whether a structural pro-
tein of the skin such as collagen VII would
be able to home to skin, incorporate into
the BMZ, and form AF after systemic
injection had never been addressed pre-
viously. Indeed, protein replacement ther-
apy is usually used in systemic diseases
such as hemophilia or in lysosomal sto-
rage disorders, in which systemic delivery
of a normal recombinant protein into the
circulation allows it to reach therapeutic
levels in the relevant target organs
(Desnick and Schuchman, 2012).
To answer this question, Woodley et al.
(2013) used venous tail injection of
human recombinant type VII collagen in
two immunodeficient murine models. In
the first model, human C7 was injected
intravenously into a wild-type mice with
full-thickness skin wounds. C7 homed to
the wounded skin only, where it formed
AF as shown by electron microscopy, and
it improved wound healing. In the second
model, C7 was injected intravenously in a
murine model with grafted murine RDEB
skin. C7 homed only to the RDEB skin
graft, and it restored DE adhesion, type VII
collagen expression, and AF formation. In
both of these models, the contribution of
human C7 to AF formation was confir-
med by immunogold labeling using gold
particles attached to an antibody specific
for human C7. Remarkably, the injected
human type VII collagen remained stably
incorporated in the BMZ for at least 3
months after one injection.
These experiments could be under-
taken because C7, in contrast to other
collagens, is soluble, and it does not
form aggregates in the blood circulation.
Still, it was anticipated that intrave-
nously injected recombinant type VII
collagen would home to skin, although
this homing was restricted to sites of
wounding. Several questions remain:
(1) how do circulating C7 molecules
escape from proteolytic degradation
while in the blood and in the skin,
(2) how do these very large homotrimers
with a molecular size of 900,000 dal-
tons reach wound sites, and (3) how are
they retained at these sites to form AF?
Passive diffusion of C7 molecules and
selective binding of C7 to exposed
laminin 332 and type IV collagen motifs
could contribute to skin homing in
wounded areas. However, each homo-
trimer subsequently needs to undergo
several critical biochemical steps for
proper structural supramolecular assem-
bly into AF, reflecting the remarkable
intrinsic properties of C7 molecules.
How can these results translate into
clinical applications?
Translation of these results from a mouse
model weighing 35 grams injected with
60mg of C7 protein to children and adults
weighing 35–70kg would need a dose of
60–120mg of C7 per infusion, respec-
tively, which does seem achievable.
However, several steps are still required
before translating these preclinical results
into clinical trials in patients. A ‘‘proof of
principle’’ in large immune-competent
animals such as Golden Retriever dogs
affected with RDEB would be a significant
step. Such studies would provide essential
information about the doses and frequen-
cies of collagen infusions that would be
required, about the efficiency and
mechanisms of AF formation, and about
potential immune tolerance to human C7.
Pharmacological and toxicology studies
using such large animals would probably
be mandatory before phase 1 clinical
studies are proposed to evaluate the safety
of systemic injections of C7 in normal
human controls.
Protein replacement using C7 via
intravenous delivery is attractive for
several reasons.
1. It has the potential to treat multiple
wounded areas of the skin and mucous
membranes simultaneously. This would
represent a major advantage over exist-
ing strategies, with the exception of
bone marrow transplantation, which
require several intradermal injections
or skin transplantation at multiple sites,
and for mucosal lesions, which are not
accessible. Treating mucosal lesions is
highly relevant in severe RDEB, as oral
and esophageal lesions often lead to
severe complications such as micro-
stomia, ankyloglossia, and stenosis of
the esophagus, which are difficult to
treat, contribute to severe malnutrition,
and have a strong impact on the
quality of life. Ocular lesions could
also be potentially improved.
2. There is a long-standing experience
and ‘‘know-how’’ about the pharma-
ceutical production of human recom-
binant proteins for clinical application,
and the final therapeutic product
involves neither viruses nor living cells,
a major advantage for safety issues and
approval by regulatory agencies.
3. Because infusion is simple and rea-
sonably comfortable for patients, this
approach would allow early thera-
peutic intervention, as soon as the
diagnosis of RDEB was confirmed
and after testing for immune toler-
ance for C7. If successful, early
intervention would have the poten-
tial of preventing severe complica-
tions, such as fusion and contracture
of fingers and esophageal stenosis.
4. This approach is not dependent on
the nature or the location of COL7A1
mutations, and thus could potentially
be applied to all RDEB patients,
provided that they did not develop
immunity to C7.
5. The high stability of C7 favors long-
term AF formation and infrequent C7
injections.
Clinical Implications
 Recessive dystrophic epidermolysis bullosa (RDEB) is a heritable
mechano-bullous skin disease characterized by skin fragility, separation
of the epidermis from the dermis, milia formation, and scarring. It is
caused by mutations in COL7A1-encoding type VII collagen, which forms
anchoring fibrils at the basement membrane zone.
 By using intravenous injection of recombinant human type VII collagen,
Woodley et al. (2013) report restoration of anchoring fibril formation and
dermal–epidermal adherence in a mouse model of RDEB.
 Although the pathway toward clinical application seems obvious, major
investigative and regulatory hurdles must be addressed before it becomes
available to patients and their physicians.
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Unanswered questions about treating
patients with C7 infusions include the
following:
1. This is the first time that a structural
protein of the skin would be delivered
intravenously to treat a genetic skin
disease. We therefore lack informa-
tion about the feasibility, efficiency,
and safety of this approach in patients
when adapting and ‘‘scaling up’’ from
murine and dog models to humans.
We do not know whether newly
formed AF will fulfill the established
ultrastructural roles of normal AF.
2. As with other protein replacement
therapies, the duration of the effects
will be transient and will depend on
the effectiveness of C7 homing to the
skin and the half-life of the protein
in vivo.
3. The overall risks of the procedure
with respect to thrombus formation,
production of anti-C7 antibodies,
and C7 deposition in vital organs
remain to be determined in larger
immune-competent animals.
4. Most of all, repetitive administration
of human C7 may favor an unwanted
immune response to C7. Therefore,
special treatments to induce toler-
ance will need to be considered,
especially in patients at risk to mount
such responses.
Immune tolerance
With the exception of bone marrow
transplantation, the gene, cell, and pro-
tein therapy strategies for RDEB expose
patients to the risks of unwanted
immune responses against normal type
VII collagen molecules. Previous studies
in RDEB immune-competent murine
models have shown that intradermal
injection of human C7 leads to the
development of circulating antibodies
against C7. However, in these studies,
the antibodies were present at very low
concentrations, were not bound to the
BMZ, and did not impair AF formation
during subsequent C7 injections
(Remington et al., 2009). The extent to
which these results will apply to humans
is unknown. The absence or presence of
the residual mutant C7 protein in
patients with RDEB will primarily
determine the immunologic response
to protein replacement. Previous work
using ELISPOT analysis of RDEB patients
suggests that patients expressing some
levels of mutated type VII collagen
molecules tolerate normal C7, where-
as patients showing no detectable
expression mount an immune response
to C7 (Pendaries et al., 2010). The
nature and location of the missing C7
epitopes, especially in the NC1 region
of the molecule, and the HLA genotype
will impact on immune tolerance of
each patient.
Perspectives
Correcting a genetic skin disease by
intravenous replacement of a defective
structural protein is a new concept, and
the results presented by Woodley et al.
(2013) raise significant hopes for future
translation into clinical practice.
Although a first step in protein
replacement therapy is currently under
development by the same group using
intradermal injection of human recom-
binant C7 in a limited skin area of RDEB
patients, intravenous delivery of C7
would open new prospects of treat-
ment. This perspective has already
aroused the interest of the pharma-
ceutical industry, and the investment of
the private industry into this project
should foster its translation to clinical
application. A better understanding of
the mechanisms governing C7 diffusion,
binding, and association with the ECM
would be advisable, as these results are
translated into clinical use. Safety issues
to be addressed should include
preclinical testing in larger immune-
competent RDEB animals and careful
investigation of immune tolerance to C7
in RDEB patients. Whether a similar
approach could be applied to other
forms of recessive EB, such as
junctional epidermolysis bullosa (JEB),
remains unknown. Indeed, protein
replacement has been achieved success-
fully in vitro for JEB by Jouni Uitto’s
group (Igoucheva et al., 2008), but the
fact that each laminin 332 chain
requires ER maturation before assembly
could make protein replacement more
challenging in that disease. Finally, it is
possible that systemic delivery of human
type VII collagen or other extracellular
matrix molecules and growth factors
could be considered for wider
applications, including the healing of
wounds in non-RDEB patients.
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